J
Juliann Chmielecki
Researcher at AstraZeneca
Publications - 124
Citations - 16230
Juliann Chmielecki is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 45, co-authored 117 publications receiving 12742 citations. Previous affiliations of Juliann Chmielecki include Massachusetts Institute of Technology & Broad Institute.
Papers
More filters
Journal ArticleDOI
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Jeffrey S. Ross,Jeffrey S. Ross,Kai Wang,Geoff Otto,Emily White,Kiel Iwanik,Gary A. Palmer,Roman Yelensky,Doron Lipson,Juliann Chmielecki,Rachel L. Erlich,Andrew Rankin,Siraj M. Ali,Julia A. Elvin,Deborah Morosini,Vincent A. Miller,Philip J. Stephens +16 more
TL;DR: Almost all CUP samples harbored at least 1 clinically relevant GA with potential to influence and personalize therapy and the ACUP tumors were more frequently driven by GAs in the highly druggable RTK/Ras/mitogen-activated protein kinase (MAPK) signaling pathway than the non-ACUP tumors.
Journal ArticleDOI
Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study
James Chih-Hsin Yang,Sang We Kim,Dong Wan Kim,Jong Seok Lee,Byoung Chul Cho,Jin Seok Ahn,Dae H. Lee,Tae Min Kim,Jonathan W. Goldman,Ronald B. Natale,Andrew P. Brown,Barbara Collins,Juliann Chmielecki,Karthick Vishwanathan,Karthick Vishwanathan,Ariadna Mendoza-Naranjo,Myung-Ju Ahn +16 more
TL;DR: Osimertinib showed meaningful therapeutic efficacy in the CNS and a manageable safety profile at 160 mg once daily in patients with EGFRm NSCLC and LM and the adverse event and PK profiles were consistent with previous reports for osimert inib.
Journal ArticleDOI
Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
Vassiliki A. Papadimitrakopoulou,Y-L. Wu,J. Y. Han,Myung-Ju Ahn,Suresh S. Ramalingam,Thomas John,Isamu Okamoto,J.C.-H. Yang,Krishna C. Bulusu,G. Laus,Barbara Collins,J.C. Barrett,Juliann Chmielecki,Tony Mok +13 more
TL;DR: This work presents a new approach to traditional and adoptive oncology that combines cell reprograming, known as “complementary and replacement therapy,” which was developed at the University of Texas MD Anderson Cancer Center in Houston with real-time real-world data.
Journal ArticleDOI
A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events
Angela N. Brooks,Angela N. Brooks,Peter S. Choi,Peter S. Choi,Luc de Waal,Luc de Waal,Tanaz Sharifnia,Tanaz Sharifnia,Marcin Imielinski,Marcin Imielinski,Gordon Saksena,Chandra Sekhar Pedamallu,Chandra Sekhar Pedamallu,Andrey Sivachenko,Mara Rosenberg,Juliann Chmielecki,Juliann Chmielecki,Michael S. Lawrence,David S. DeLuca,Gad Getz,Matthew Meyerson,Matthew Meyerson +21 more
TL;DR: It is found that S34F/Y mutations cause preferences for CAG over UAG 3′ splice site sequences, which is consistent with the function of U2AF1 in 3′splice site recognition, and shows consistent effects of U 2AF1 mutation on splicing in distinct cancer cell types.
Journal ArticleDOI
FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
Eileen Shi,Juliann Chmielecki,Chih-Min Tang,Kai Wang,Michael Heinrich,Guhyun Kang,Guhyun Kang,Christopher L. Corless,David S. Hong,Katherine E. Fero,James D. Murphy,Paul T. Fanta,Siraj M. Ali,Martina De Siena,Adam M. Burgoyne,Sujana Movva,Lisa Madlensky,Gregory M. Heestand,Jonathan C. Trent,Razelle Kurzrock,Deborah Morosini,Jeffrey S. Ross,Olivier Harismendy,Jason K. Sicklick +23 more
TL;DR: Using patient demographics, tumor characteristics, and CGP, it is shown that GIST lacking alterations in canonical genes occur in younger patients, frequently metastasize to lymph nodes, and most contain deleterious genomic alterations, including gene fusions involving FGFR1 and NTRK3.